Neon Therapeutics (NASDAQ: NTGN) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Neon Therapeutics to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings.

Earnings & Valuation

This table compares Neon Therapeutics and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Neon Therapeutics N/A -$76.93 million -1.13
Neon Therapeutics Competitors $897.63 million $190.37 million -1.33

Neon Therapeutics’ competitors have higher revenue and earnings than Neon Therapeutics. Neon Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

70.0% of Neon Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Neon Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neon Therapeutics N/A -122.27% -65.61%
Neon Therapeutics Competitors -5,144.22% -64.24% -27.96%

Analyst Ratings

This is a summary of recent ratings for Neon Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neon Therapeutics 0 0 4 0 3.00
Neon Therapeutics Competitors 834 2774 6059 261 2.58

Neon Therapeutics currently has a consensus target price of $19.20, indicating a potential upside of 206.22%. As a group, “Biological products, except diagnostic” companies have a potential upside of 33.35%. Given Neon Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Neon Therapeutics is more favorable than its competitors.

About Neon Therapeutics

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.